By way of comparison, minimal residual disease accounts for a theoretical 39.4% of relapse in high-risk ALL, while the novel feature of high CRLF2 expression accounts for 13.1% of relapse among all children with ALL. Here, CRLF2 is linked to acute lymphoblastic leukemia.